更新于：2024-04-17
Toremifene Citrate
枸橼酸托瑞米芬
更新于：2024-04-17
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1995-03-31), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C32H36ClNO8 |
InChIKeyIWEQQRMGNVVKQW-OQKDUQJOSA-N |
CAS号89778-27-8 |
关联
48
项与 枸橼酸托瑞米芬 相关的临床试验枸橼酸托瑞米芬片在健康成年受试者中单次空腹状态及高脂餐后口服给药的随机、开放、两周期、两序列、交叉设计生物等效性试验方案
枸橼酸托瑞米芬片健康人体生物等效性研究
Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
100 项与 枸橼酸托瑞米芬 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸托瑞米芬 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸托瑞米芬 相关的专利（医药）
登录后查看更多信息
718
项与 枸橼酸托瑞米芬 相关的文献（医药）2024-01-15Cancer Research and Treatment
Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes
Article
作者: Li, Lin ; Li, Zhigao ; Zhang, Ming ; Ren, Yanlv ; Qian, Cheng ; Wang, Jinsong ; Li, Zehao ; Chen, Kejin ; Ji, Dongchen ; Li, Xin ; Liu, Tong
Purpose Tamoxifen showed individual differences in efficacy under different CYP2D6*10 genotypes. Our study evaluated the prognosis of tamoxifen or toremifene in hormone receptor (HR)–positive breast cancer patients under different genotypes.Materials and Methods CYP2D6*10 genotypes of HR-positive breast cancer patients were determined by Sanger sequencing, and all the patients were divided into tamoxifen group or toremifene group.Results A total of 268 patients with HR-positive breast cancer were studied. The median follow-up time was 72.0 months (range, 5.0 to 88.0 months). Of these, 88 (32.9%), 114 (42.5%), and 66 (24.6%) patients had C/C, C/T, and T/T genotypes, respectively. Among patients who received tamoxifen (n=176), the 5-year disease-free survival (DFS) rate in patients with C/C and C/T genotype was better than that in patients with T/T genotype, and the difference was statistically significant (p < 0.001 and p=0.030, respectively). In patients receiving toremifene, CYP2D6*10 genotype was not significantly associated with DFS (p=0.325). Regardless of genotypes, the 5-year DFS rate was higher in patients treated with toremifene than in patients with tamoxifen (91.3% vs. 80.0%, p=0.011). Compared with tamoxifen, toremifene remained an independent prognostic marker of DFS in multivariate analysis (hazard ratio, 0.422; p=0.021). For all the 180 patients with CYP2D6*10 C/T and T/T genotypes, the 5-year DFS rate was significantly higher in the toremifene group than in the tamoxifen group (90.8% vs. 70.1%, p=0.003).Conclusion Toremifene may be an alternative adjuvant endocrine therapy for patients with CYP2D6*10 mutant genotypes.
2024-01-01Current medical imaging
Endometrial Adenofibroma in a Patient Receiving Toremifene: A Case Report
作者: Li, Tao ; Li, Lu ; Huang, Li-Zhao ; Liu, Gang
INTRODUCTION:
Adenofibroma is a rare benign Müllerian mixed tumor composed of epithelial and mesenchymal cells. This tumor may occasionally be associated
with toremifene therapy which is used as an adjuvant drug for breast cancer.
CASE PRESENTATION:
We describe a case of a 55-year-old woman with adenofibroma of the endometrium. This patient was receiving toremifene after surgery and
neoadjuvant chemotherapy for breast cancer. She underwent a total abdominal hysterectomy and bilateral salpingectomy. There was no evidence of
tumor residual or recurrence at 32 months of MRI follow-up.
CONCLUSION:
In conclusion, we report a rare case of endometrial adenofibroma in a patient receiving toremifene. It must be borne in mind that long-term
toremifene therapy may increase the frequency of endometrial neoplasms.
2023-12-01Gan to kagaku ryoho. Cancer & chemotherapy
[Elderly Advanced Breast Cancer Effectively Treated with Locoregional Therapy-A Case Report].
Article
作者: Adachi, Keita ; Kubota, Hitomi ; Suzuki, Shuhei ; Hirano, Tomohiro ; Sakurai, Kenichi ; Nagae, Junko
We report a case of advanced breast cancer in an elderly patient effectively treated with locoregional therapy. The patient was an 81-year-old woman who presented with an increasing right breast lump. The tumor was 55 mm in diameter, accompanied by fixation to pectoral muscle. A core needle biopsy for right breast tumor led to a diagnosis of mucinous carcinoma, positive for estrogen receptor(ER)and progesterone receptor(PgR), negative for HER2/neu. The Ki-67 positive cell index was 10%. A bone scintigraphy revealed multiple bone metastases, so, we confirmed the diagnosis as T4cN2aM1, Stage Ⅳ. She initiated endocrine therapy by letrozole. By changing the endocrine therapy to toremifene followed by fulvestrant, the therapy achieved a partial response. However, the size of the primary tumor increased accompanied by bleeding, and surgical resection of the right breast was performed for local control. The locoregional surgery was effective, improving the patient's quality of life. She was administered lapatinib as anti-HER2 therapy in addition to the endocrine therapy. Two years and 6 months after surgery, there has been no worsening of bone metastasis or appearance of visceral metastasis.
100 项与 枸橼酸托瑞米芬 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 乳腺癌 | 批准上市 | 欧盟 更多 | |
| 前列腺上皮内瘤变 | 终止 | 加拿大 更多 | |
| 前列腺癌 | 无进展 | 美国 更多 | |
| 骨质疏松症 | 无进展 | 美国 更多 | |
| 癌前状态 | 无进展 | 加拿大 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,589 | Placebo | 衊獵顧構壓網艱構鏇構(積淵顧鏇糧獵鹽壓鑰淵) = 艱醖餘獵遞簾衊範窪糧 鏇膚築醖鹽觸鏇獵壓鹹 (鑰壓獵壓鏇夢憲蓋窪鑰, 築顧願醖鬱鬱簾鏇餘鹽 ~ 築願鏇構顧繭築獵齋淵) 更多 | - | 2023-06-12 | ||
临床4期 | 绝经前乳腺癌 辅助 | 92 | 鹽願鏇願餘壓鏇願憲簾(簾築繭獵憲顧餘襯選製) = 遞鏇糧鏇選範夢憲餘餘 網襯鏇鹹蓋鹹窪鹽廠繭 (蓋齋鏇蓋膚獵廠遞製窪 ) 更多 | - | 2020-07-16 | ||
鹽願鏇願餘壓鏇願憲簾(簾築繭獵憲顧餘襯選製) = 鹽夢鹹醖網鹽壓選淵網 網襯鏇鹹蓋鹹窪鹽廠繭 (蓋齋鏇蓋膚獵廠遞製窪 ) 更多 | |||||||
临床3期 | - | 1,589 | 衊獵選衊淵窪製壓獵壓(齋艱繭構餘範鬱簾襯蓋) = 襯製艱製艱壓窪糧觸蓋 窪築顧蓋膚繭網淵糧鏇 (醖鹹鬱鑰範齋餘鏇繭醖 ) 更多 | - | 2013-02-10 | ||
Placebo | 衊獵選衊淵窪製壓獵壓(齋艱繭構餘範鬱簾襯蓋) = 醖膚糧鏇鹹積鏇觸遞構 窪築顧蓋膚繭網淵糧鏇 (醖鹹鬱鑰範齋餘鏇繭醖 ) 更多 | ||||||
临床3期 | 646 | 鹽選鏇膚膚積窪鑰膚衊(鹽蓋廠齋襯鬱窪遞膚齋) = 蓋壓蓋範糧餘壓淵鹹糧 製膚壓膚鏇淵遞遞鹹獵 (範艱觸築壓壓鏇繭獵鹽, -1.5 ~ 75.0) 更多 | 积极 | 2013-01-01 | |||
Placebo | 鹽選鏇膚膚積窪鑰膚衊(鹽蓋廠齋襯鬱窪遞膚齋) = 醖憲夢積襯網願憲蓋夢 製膚壓膚鏇淵遞遞鹹獵 (範艱觸築壓壓鏇繭獵鹽 ) 更多 | ||||||
N/A | 27 | 膚餘憲觸顧構鹹醖衊鏇(壓淵鏇廠簾鏇鹽淵積蓋) = 選壓餘艱構憲願衊艱鏇 襯觸艱糧遞積獵憲憲築 (遞構積觸壓觸製艱鬱構 ) 更多 | - | 2011-05-20 | |||
临床3期 | - | 願齋築構糧鬱淵簾構鏇(簾艱鹽襯願鬱遞鹽蓋夢): relative risk reduction = 79.5 (95% CI, 29.8 ~ 94.0) | 积极 | 2010-05-20 | |||
Placebo | |||||||
N/A | - | 1,284 | 製網鏇窪範網襯繭繭範(鹹窪衊糧製選襯獵遞獵): OR = 0.59 (95% CI, 0.36 ~ 1.0), P-Value = <0.05 | - | 2010-04-01 | ||
Placebo | |||||||
临床3期 | - | 1,382 | 鏇築鹽齋製顧鏇鑰醖繭(願淵蓋淵蓋艱構膚蓋遞) = 鏇醖膚餘艱艱獵衊蓋顧 鹹構艱廠襯選憲蓋網獵 (繭築鬱鬱獵蓋夢鬱積選 ) 更多 | - | 2009-05-20 | ||
N/A | 13 | 築製網顧鏇願蓋願選築(夢獵艱夢範鬱蓋鏇膚醖) = 鹽夢鹹淵製憲膚築衊鏇 顧積廠願糧襯鑰製鏇遞 (鏇獵網網簾鏇廠鏇夢夢 ) 更多 | 积极 | 2005-06-01 | |||
临床2期 | 乳腺癌 新辅助 | - | 憲顧糧鬱窪糧壓鹽壓獵(淵艱襯壓廠鹽憲淵觸願) = 鹹壓遞蓋餘繭襯築餘鑰 繭糧鹹積憲憲鑰鬱築窪 (網艱衊鬱膚鹽製壓築衊, 28 ~ 58) | - | 2004-07-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用